Clinical and Applied Thrombosis/Hemostasis (Sep 2021)

The Application of the ThroLy Risk Assessment Model to Predict Venous Thromboembolism in Patients with Diffuse Large B-Cell Lymphoma

  • Hikmat Abdel-Razeq,
  • Mohammad Ma’koseh,
  • Asem Mansour,
  • Rayan Bater,
  • Rula Amarin,
  • Alaa Abufara,
  • Khalid Halahleh,
  • Mohammad Manassra,
  • Mohammad Alrwashdeh,
  • Mohammad Almomani,
  • Mais Zmaily

DOI
https://doi.org/10.1177/10760296211045908
Journal volume & issue
Vol. 27

Abstract

Read online

Background Patients with aggressive lymphomas are at higher risk for venous thromboembolism (VTE). ThroLy is a risk assessment model (RAM) derived to predict the occurrence of VTE in various types of lymphomas. In this study, we assess the clinical application of ThroLy RAM in a unified group of patients with diffuse large B-cell lymphoma (DLBCL). Methods Hospital databases were searched for patients with DLBCL and radiologically-confirmed VTE. Items in the ThroLy RAM, including prior VTE, reduced mobility, obesity, extranodal disease, mediastinal involvement, neutropenia and hemoglobin 3) ThroLy score, 22.3% developed VTE compared to 8.4% and 12.4% in those with low and intermediate risk scores, respectively ( P = .014). Simplifying the ThroLy model into two risk groups; high-risk (score ≥ 3) and low risk (score < 3) can still segregate patients; VTE developed in 44 (17.2%) high-risk patients ( n = 256) compared to 27 (10.1%) in the low-risk group ( n = 268), P = .038. Neutropenia, a component of the ThroLy, was encountered in only 14 (2.7%) patients. Conclusions ThroLy RAM can identify patients with DLBCL at high risk for VTE. Model can be modified by dividing patients into two, rather than three risk groups, and further simplified by omitting neutropenia.